UNSPSC 51182034: Mibolerone

This classification denotes a therapeutic androgen with the molecular formula C20H30O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9OGY4BOR8D, chemically known as 19-nortestosterone, 7alpha,17-dimethyl- but generally known as mibolerone, which bears US NIH Compound Identifier 19454. European Medicines Agency schedules Mibolerone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08941MIG.

UNSPSC 51182034 Mibolerone is a Commodity code representing anabolic steroid pharmaceuticals and related controlled-substance actives procured by state and local health systems, correctional facilities, and public health agencies. State and local governments procure these products through cooperative purchasing alliances and direct procurement vehicles as components of broader pharmaceutical supply agreements, typically bundled with generic multi-source drugs and over-the-counter products for distribution across institutional networks. Issuing bodies include state departments of administration overseeing multistate cooperative purchasing programs, state health departments, county health systems, and public correctional agencies. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents a primary vehicle through which participating state and local governments source these products across multiple jurisdictions.

Recent activity centers on the MMCAP Generic Multi Source Pharmaceuticals and OTC Products RFP (Solicitation S1070000015802), posted January 20, 2026, with proposals due March 26, 2026. The procurement establishes multi-award contracts for pharmaceutical products including mibolerone and other controlled actives to be sourced through three authorized wholesalers (AmerisourceBergen Drug Corporation / Cencora, Cardinal Health, and Morris & Dickson Co.), with awarded pricing effective July 1, 2026. Vendors must certify cGMP and Drug Supply Chain Security Act compliance, maintain relationships with at least two of the three authorized wholesalers with chargeback systems, and carry commercial general liability insurance of $5,000,000 per occurrence. Evaluation weights price competitiveness at 75 percent, with secondary criteria including fixed pricing structures (10 percent), EDI capability (5 percent), and administrative compliance (10 percent). The RFP encompasses participating jurisdictions in Minnesota and Oregon; contract terms are two years for new vendors with optional extensions, or alignment with existing expiration dates through June 30, 2028 for incumbents.